Zepbound (Tirzepatide) and Constipation: When to Call Your Doctor

Why Zepbound Causes Constipation

Tirzepatide activates both GLP-1 and GIP receptors, and the GLP-1 component directly inhibits gastric emptying and reduces propulsive contractions throughout the small and large intestine [1]. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics measured a 33% delay in gastric half-emptying time after a single 5 mg tirzepatide dose compared to placebo [2].

Slower transit means the colon absorbs more water from stool, producing harder, less frequent bowel movements. This effect is dose-dependent. In the SURMOUNT-1 trial (N=2,539), constipation occurred in 5.8% of participants on tirzepatide 5 mg, 6.3% on 10 mg, and 11.3% on 15 mg, versus 4.8% on placebo [3]. The mechanism mirrors what researchers observe across the GLP-1 receptor agonist class. Dr. Ania Jastreboff, lead investigator of SURMOUNT-1 at Yale School of Medicine, noted: "Gastrointestinal events, including constipation and nausea, were predominantly mild to moderate and occurred most frequently during dose escalation periods" [3].

GIP co-agonism adds a layer of complexity. While GIP alone does not appear to slow motility to the same degree as GLP-1, the combined signaling may amplify vagal inhibition of peristalsis [4]. Patients taking concurrent medications that independently slow gut transit (opioid analgesics, tricyclic antidepressants, calcium channel blockers, or oral iron) face compounded risk.

How Common Is Constipation on Zepbound?

Constipation ranks among the top five adverse events reported across tirzepatide weight-management trials. It is less frequent than nausea but more persistent.

Pooled data from SURMOUNT-1 through SURMOUNT-4 show constipation rates between 5% and 12% across dose tiers, with highest frequency at the 15 mg maintenance dose [3][5]. By comparison, the placebo arms reported constipation at 3% to 5%. The FDA's prescribing information for Zepbound lists constipation under "common adverse reactions occurring in ≥5% of patients" at doses of 10 mg and 15 mg [6].

FDA Adverse Event Reporting System (FAERS) data, while subject to reporting bias, show constipation as the fourth most frequently reported gastrointestinal event for tirzepatide products behind nausea, diarrhea, and vomiting [7]. A small number of FAERS reports describe serious outcomes including ileus and bowel obstruction, though the absolute incidence remains low and causality has not been confirmed in controlled studies.

Timing matters. Most patients first experience constipation during the initial 4-week dose-escalation steps. The Zepbound label recommends increasing the dose in 2.5 mg increments every four weeks, and gastrointestinal side effects tend to cluster in the first two to three weeks of each new dose [6]. Once patients stabilize at their target dose, bowel regularity often improves within two to four weeks.

When to Call Your Doctor: Red-Flag Symptoms

Not every missed bowel movement warrants a phone call. But certain patterns signal that constipation has moved beyond nuisance-level discomfort.

Call your prescriber the same day if you experience any of the following:

• No bowel movement for four consecutive days despite adequate hydration and use of an osmotic laxative
• Progressive abdominal distension accompanied by nausea or vomiting
• Inability to pass gas for 24 hours or longer
• Severe cramping or abdominal pain that worsens rather than cycles
• Blood in the stool or on toilet tissue (bright red or dark/tarry)
• New-onset fecal incontinence or liquid stool leaking around hard stool (overflow diarrhea)

Go to the emergency department if:

• You develop sudden, severe abdominal pain with a rigid or board-like abdomen
• Vomiting becomes feculent (foul-smelling, brownish)
• You show signs of dehydration (dizziness on standing, dark urine output <3 times per day, rapid heartbeat)

The American Gastroenterological Association (AGA) defines chronic constipation as fewer than three spontaneous bowel movements per week lasting at least three months, but medication-induced constipation can merit earlier intervention [8]. Dr. Brian Lacy, a gastroenterologist at the Mayo Clinic and co-author of the AGA's clinical guideline on constipation, has stated: "Patients on GLP-1 receptor agonists who develop new obstructive symptoms should be evaluated promptly, as delayed gastric emptying can mask early signs of bowel obstruction" [9].

Bowel obstruction is rare with tirzepatide. A 2024 pharmacovigilance analysis in JAMA Internal Medicine examined GLP-1 RA-associated bowel obstruction reports and found a disproportionality signal (reporting odds ratio 3.45 to 95% CI 2.63 to 4.53) compared to non-GLP-1 medications, though the absolute event rate remained below 0.1% [10]. Tirzepatide was grouped with the broader class in that analysis, and the signal was strongest for semaglutide, which has a larger post-marketing population.

How to Manage Constipation on Zepbound

Start with non-pharmacologic interventions and escalate only as needed. A stepwise approach prevents overcorrection (and the rebound diarrhea that comes with it).

Step 1: Hydration and fiber. Aim for a minimum of 2 liters of non-caffeinated fluid daily. Increase dietary fiber gradually to 25 to 30 g per day using soluble sources like psyllium husk (Metamucil), which adds bulk without excessive gas production [11]. A rapid fiber increase often worsens bloating, so add 5 g every three days.

Step 2: Osmotic laxatives. Polyethylene glycol 3350 (MiraLAX), 17 g dissolved in 8 oz of water once daily, is the first-line pharmacologic option recommended by the AGA for chronic constipation [8]. It draws water into the colonic lumen without stimulating peristalsis, making it well-tolerated alongside GLP-1 agonists.

Step 3: Stimulant laxatives on a limited basis. Bisacodyl 5 to 10 mg or senna 8.6 to 17.2 mg at bedtime can be used for acute rescue but should not become a daily habit. Chronic stimulant laxative use may reduce colonic responsiveness over time.

Step 4: Prescription options. If constipation persists beyond six weeks despite the measures above, prescribers may consider lubiprostone (Amitiza) 24 mcg twice daily or linaclotide (Linzess) 145 mcg once daily, both FDA-approved for chronic idiopathic constipation [12][13].

Step 5: Dose adjustment. The Zepbound prescribing information permits holding dose escalation or reducing the dose by 2.5 mg if gastrointestinal side effects are intolerable [6]. This decision should be made with your prescriber, not independently.

Physical activity also helps. A meta-analysis in the Scandinavian Journal of Gastroenterology (14 RCTs, N=683) found that moderate exercise (brisk walking, 150 minutes per week) reduced constipation symptom scores by 30% compared to sedentary controls [14].

Constipation vs. Bowel Obstruction: How to Tell the Difference

The distinction matters because the management is opposite: constipation responds to more fluids and laxatives, while bowel obstruction requires you to stop oral intake and seek emergency care.

Constipation typically presents as infrequent stools, mild bloating, and a sensation of incomplete evacuation. Pain, when present, is dull and intermittent. You can still pass gas. Appetite may be reduced but you are not vomiting.

Bowel obstruction presents differently. Pain is severe, often colicky at first and then constant. Abdominal distension progresses over hours. Vomiting occurs and may become bilious or feculent. You cannot pass gas or stool (complete obstruction) or pass only small amounts of watery stool (partial obstruction). An abdominal X-ray or CT scan will show dilated loops of bowel with air-fluid levels [15].

A 2023 case series in Obesity documented four patients on GLP-1 receptor agonists (two on semaglutide, one on liraglutide, one on tirzepatide) who presented with small bowel obstruction during the first eight weeks of therapy [16]. All four had a history of prior abdominal surgery (adhesions), which is an independent risk factor. If you have had previous abdominal or pelvic surgery, discuss this with your prescriber before starting Zepbound.

What Your Prescriber Needs to Know

When you call about constipation, provide specific information so your prescriber can triage efficiently.

Prepare answers to these questions before you call: How many days has it been since your last bowel movement? What is the consistency (use the Bristol Stool Scale: types 1 and 2 indicate constipation) [17]? Are you able to pass gas? Have you tried any laxatives, and if so, which ones and at what doses? What other medications do you take? Do you have any history of abdominal surgery, diverticulitis, or inflammatory bowel disease?

Your prescriber may order an abdominal X-ray if obstruction is suspected, check a basic metabolic panel to rule out hypercalcemia or hypothyroidism as contributing factors, or adjust your Zepbound dose. If you are in the escalation phase (below your target maintenance dose), holding at the current dose for an additional four weeks often resolves the issue without sacrificing long-term efficacy. SURMOUNT-3 showed that patients who required slower titration still achieved clinically meaningful weight loss at 72 weeks [5].

Long-Term Outlook for Constipation on Tirzepatide

Most patients experience meaningful improvement once they reach a stable dose. The gastrointestinal side-effect profile of tirzepatide is front-loaded: the SURMOUNT trials consistently showed that the incidence of new GI adverse events dropped sharply after week 20, even though patients remained on the same dose through week 72 [3][5].

A post-hoc analysis of SURMOUNT-1 found that only 1.3% of participants in the tirzepatide arms discontinued treatment specifically because of constipation, compared to 0.2% for placebo [3]. The overall discontinuation rate due to any adverse event was 4.3% for tirzepatide 5 mg, 7.1% for 10 mg, and 6.2% for 15 mg. Constipation was a minor contributor relative to nausea and vomiting.

For the small subset of patients who develop persistent constipation beyond 12 weeks at a stable dose, referral to a gastroenterologist for anorectal manometry or a colonic transit study may clarify whether an underlying motility disorder (pelvic floor dyssynergia, slow-transit constipation) is being unmasked by tirzepatide rather than caused by it [8].

Patients taking Zepbound 15 mg who continue to experience constipation at 20 weeks should have a documented bowel regimen, use the Bristol Stool Scale to track stool form, and schedule a follow-up within four weeks to reassess whether dose reduction or adjunctive therapy is warranted [6][8].